Procaps Group, S.A. Overview
Pro stress-test →Procaps Group is a leading developer of pharmaceutical and nutraceutical solutions that reach more than 50 countries across all five continents, with direct presence in 13 countries in the Americas and nearly 5,000 employees. The company develops, manufactures, and markets OTC pharmaceutical products, prescription drugs, nutritional supplements, and high-potency clinical solutions.
Strategic Profile
Pro stress-test →Procaps is a leading integrated LatAm healthcare and pharmaceutical services company. However, the company faces significant near-term headwinds: in February 2025, Procaps received a delisting notice from Nasdaq due to failure to demonstrate compliance with listing rules for filing periodic and interim financial reports, resulting in the company's ordinary shares commencing trading on the OTC Expert Market on February 4, 2025.
Competitive Landscape
Pro stress-test →Procaps competes in the integrated Latin American pharmaceutical market, offering both OTC and prescription products alongside nutritional supplements and clinical solutions. Regional competitors include established pharma manufacturers across Central and South America, as well as larger multinational pharmaceutical companies with regional operations.
Industry Context
Procaps Group, S.A. operates in Latin American Pharmaceutical Manufacturing.
Key facts
Founded: 2021 · Headquarters: Bogotá, Colombia · Employees: 5000 · Revenue: N/A · Market cap: N/A